Literature DB >> 24949207

Comment on "complete androgen insensitivity syndrome: optimizing diagnosis and management".

Antonio Balsamo1, Federico Baronio1, Marta Berra2, Silvano Bertelloni3, Franco D'Alberton4, Giacinto Marrocco5, Santiago Vallasciani6.   

Abstract

Entities:  

Year:  2014        PMID: 24949207      PMCID: PMC4037611          DOI: 10.1155/2014/285715

Source DB:  PubMed          Journal:  Case Rep Obstet Gynecol        ISSN: 2090-6692


× No keyword cloud information.
We read with interest the paper of Pizzo et al. [1], confirming that adolescence is a key period for the diagnosis of 46,XY disorders of sex development (DSD) [2]. However, in our opinion, some points should be better addressed. Among these, we have the following. The authors stated that the reported girl showed “normal intellectual function,” but this information had little relevance because mental function is not impaired in females with 46,XY DSD, reaching adolescence without any clinical suspicions. Indeed, this statement might be stigmatizing for these persons. The statement that this adolescent was affected by hypergonadotropic hypogonadism (HH) is correct, according to the high LH and FSH values shown in Table 1 [1]. Very low levels of both 17β-estradiol and testosterone were also shown [1]. This endocrine pattern is not typical of late adolescent and young adult females with complete androgen insensitivity syndrome (CAIS) and intact testes. On the contrary, these persons show high/normal levels of both 17β-estradiol (for a person with a 46,XY karyotype) and testosterone [3-5]. In addition, adolescent/young adult women with CAIS did not show HH: LH is in high normal range or slightly elevated (due to the androgen resistance at central level), but FSH is in normal range (due to unaffected inhibin secretion from Sertoli cells) [3-5]. In addition, SHBG was reported within adult male range by Pizzo et al. [1], suggesting a normal sensitivity to the low levels of androgens in this girl [6]. Indeed, SHBG is within normal female range in women with CAIS, due to peripheral androgen resistance [5]. All these findings show poor agreement with the affirmed diagnosis of CAIS [1]. The clinical phenotype of the reported girl did not match with the phenotype of adolescents with CAIS; in fact, the latter shows normal breast development related to the relatively high normal estrogen levels and unopposed androgen action [3, 4, 7] and does not show hypotrophic breasts [1]. It is quite surprising that hormonal replacement therapy was started before any diagnosis was established. Histological findings do not completely agree with the diagnosis of CAIS, in particular the absence of Leydig cells, which are abundant in adolescent females with CAIS and sometimes formed aggregates up to 2 mm in diameter [8, 9]. 46,XY karyotype, female phenotype, and absence of mullerian derivatives may be present in several 46,XY DSD; they should be excluded before diagnosis of CAIS by optimal clinical, endocrine, and genetic investigations [10]. For example, the testosterone/Δ4-androstenedione ratio in the adolescent reported by Pizzo et al. [1] is very low (0.13; normal values >0.8 [11]). Thus, diagnoses of 17β-hydroxysteroid-dehydrogenase deficiency type 3 or 46,XY gonadal dysgenesis [11, 12] must be considered in the diagnostic process. Risk of gonadal cancer largely varies among 46,XY DSD. For example, in CAIS is very low at least during the first two decades of life [13-15]. Thus, delayed gonadal removal can be recommended to permit both full sexual development [15] and better bone health [16]. If diagnosis of CAIS is certain, surgery can be postponed—at least until the legal age at which the propositus can participate in decision making [1, 15, 17–19]. We are concerned and in complete disagreement with the decision to perform gonadectomy without full disclosure and assent of the adolescent [17-19]. In conclusion, some findings are poorly consistent with a diagnosis of CAIS, which should be confirmed by molecular analysis of androgen receptor gene [2, 7]. In our experience, more than 25% of the females referred to our departments with clinical/endocrine diagnosis of CAIS did not have this diagnosis confirmed by genetic analysis [20]. Clinical approach should be changed according to the new guidelines for management of persons with 46,XY DSD and directly involving the girl in the decision process [2, 18, 21]. We also stress that multidisciplinary team evaluation in tertiary centers with documented experience in this field must be guaranteed to each person with 46,XY DSD for optimal holistic management [21], especially before performing irreversible surgical procedures.
  20 in total

1.  Ethical guidelines for the clinical management of intersex.

Authors:  C Wiesemann
Journal:  Sex Dev       Date:  2010-07-10       Impact factor: 1.824

2.  17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations.

Authors:  A L Boehmer; A O Brinkmann; L A Sandkuijl; D J Halley; M F Niermeijer; S Andersson; F H de Jong; H Kayserili; M A de Vroede; B J Otten; C W Rouwé; B B Mendonça; C Rodrigues; H H Bode; P E de Ruiter; H A Delemarre-van de Waal; S L Drop
Journal:  J Clin Endocrinol Metab       Date:  1999-12       Impact factor: 5.958

Review 3.  Timing of gonadectomy in adult women with complete androgen insensitivity syndrome (CAIS): patient preferences and clinical evidence.

Authors:  Rebecca Deans; Sarah M Creighton; Lih-Mei Liao; Gerard S Conway
Journal:  Clin Endocrinol (Oxf)       Date:  2012-06       Impact factor: 3.478

4.  Novel (60%) and recurrent (40%) androgen receptor gene mutations in a series of 59 patients with a 46,XY disorder of sex development.

Authors:  L Audi; M Fernández-Cancio; A Carrascosa; P Andaluz; N Torán; C Piró; E Vilaró; E Vicens-Calvet; M Gussinyé; M A Albisu; D Yeste; M Clemente; I Hernández de la Calle; M Del Campo; T Vendrell; A Blanco; J Martínez-Mora; M L Granada; I Salinas; J Forn; J Calaf; O Angerri; M J Martínez-Sopena; J Del Valle; E García; R Gracia-Bouthelier; P Lapunzina; E Mayayo; J I Labarta; G Lledó; J Sánchez Del Pozo; J Arroyo; A Pérez-Aytes; M Beneyto; A Segura; V Borrás; E Gabau; M Caimarí; A Rodríguez; M J Martínez-Aedo; M Carrera; L Castaño; M Andrade; J A Bermúdez de la Vega
Journal:  J Clin Endocrinol Metab       Date:  2010-02-11       Impact factor: 5.958

Review 5.  Tumor risk in disorders of sex development.

Authors:  J Pleskacova; R Hersmus; J W Oosterhuis; B A Setyawati; S M Faradz; M Cools; K P Wolffenbuttel; J Lebl; S L Drop; L H Looijenga
Journal:  Sex Dev       Date:  2010-06-17       Impact factor: 1.824

6.  Testicular development in the complete androgen insensitivity syndrome.

Authors:  S E Hannema; I S Scott; E Rajpert-De Meyts; N E Skakkebaek; N Coleman; I A Hughes
Journal:  J Pathol       Date:  2006-03       Impact factor: 7.996

Review 7.  Bone health in disorders of sex differentiation.

Authors:  S Bertelloni; G I Baroncelli; S Mora
Journal:  Sex Dev       Date:  2010-09-04       Impact factor: 1.824

8.  NR5A1 gene mutations: clinical, endocrine and genetic features in two girls with 46,XY disorder of sex development.

Authors:  Silvano Bertelloni; Eleonora Dati; Fulvia Baldinotti; Benedetta Toschi; Giacinto Marrocco; Maria R Sessa; Angela Michelucci; Paolo Simi; Giampiero I Baroncelli
Journal:  Horm Res Paediatr       Date:  2014-01-16       Impact factor: 2.852

9.  Complete androgen insensitivity syndrome: factors influencing gonadal histology including germ cell pathology.

Authors:  Jana Kaprova-Pleskacova; Hans Stoop; Hennie Brüggenwirth; Martine Cools; Katja P Wolffenbuttel; Stenvert L S Drop; Marta Snajderova; Jan Lebl; J Wolter Oosterhuis; Leendert H J Looijenga
Journal:  Mod Pathol       Date:  2013-11-01       Impact factor: 7.842

Review 10.  Androgen insensitivity syndrome.

Authors:  Ieuan A Hughes; John D Davies; Trevor I Bunch; Vickie Pasterski; Kiki Mastroyannopoulou; Jane MacDougall
Journal:  Lancet       Date:  2012-06-13       Impact factor: 79.321

View more
  1 in total

1.  Response to: Comment on "Complete Androgen Insensitivity Syndrome: Optimizing Diagnosis and Management".

Authors:  Antonio Simone Laganà; Alfonsa Pizzo
Journal:  Case Rep Obstet Gynecol       Date:  2014-12-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.